Ruwen Böhm1, Ehrhardt Proksch, Thomas Schwarz, Ingolf Cascorbi. 1. Institute of Clinical and Experimental Pharmacology at the University Medical Center Schleswig-Holstein, Kiel; Department of Dermatology, Allergology and Venerology, University Medical Center Schleswig-Holstein, Kiel.
Abstract
BACKGROUND: Adverse drug reactions (ADRs) can be divided into pharmacological ADRs (type A) and hypersensitivity reactions (type B). Type B reactions can be further subdivided into immediate (<1 h, urticaria, anaphylaxis) and delayed reactions (>1 h, variable manifestation like exanthema, hepatitis, cytopenias). Prevention of hypersensitivity is often still a challenge. METHODS: Selective literature search in Medline and Google Scholar as well as research in ADR databases like OpenVigil or SIDER. RESULTS: Laboratory tests ([specific] IgE, lymphocyte transformation test), histological examination, dermatological tests (prick tests, epicutaneous testing) and-under certain circumstances-provocation tests can be used for diagnostics. There are only a few pharmacogenetic biomarkers to predict hypersensitivity reactions. Currently, testing for defined HLA genes is mandatory before prescription of abacavir and before the use of carbamazepine in Han Chinese or Thai patients. Immediate discontinuation of the trigger is essential in all allergic hypersensitivity reactions. Immediate reactions are treated with antihistamines, glucocorticoids and occasionally with epinephrine. Delayed reactions are usually treated with glucocorticoids. CONCLUSION: Careful, structured diagnostics in case of suspected hypersensitivity together with adequate documentation (allergy passport) is necessary in order to avoid incidents in patients receiving subsequent treatment. Consistent use of existing resources (diagnostics and documentation) can help to avoid hypersensitivity reactions or to rapidly recognize and treat them, respectively.
BACKGROUND: Adverse drug reactions (ADRs) can be divided into pharmacological ADRs (type A) and hypersensitivity reactions (type B). Type B reactions can be further subdivided into immediate (<1 h, urticaria, anaphylaxis) and delayed reactions (>1 h, variable manifestation like exanthema, hepatitis, cytopenias). Prevention of hypersensitivity is often still a challenge. METHODS: Selective literature search in Medline and Google Scholar as well as research in ADR databases like OpenVigil or SIDER. RESULTS: Laboratory tests ([specific] IgE, lymphocyte transformation test), histological examination, dermatological tests (prick tests, epicutaneous testing) and-under certain circumstances-provocation tests can be used for diagnostics. There are only a few pharmacogenetic biomarkers to predict hypersensitivity reactions. Currently, testing for defined HLA genes is mandatory before prescription of abacavir and before the use of carbamazepine in Han Chinese or Thai patients. Immediate discontinuation of the trigger is essential in all allergic hypersensitivity reactions. Immediate reactions are treated with antihistamines, glucocorticoids and occasionally with epinephrine. Delayed reactions are usually treated with glucocorticoids. CONCLUSION: Careful, structured diagnostics in case of suspected hypersensitivity together with adequate documentation (allergy passport) is necessary in order to avoid incidents in patients receiving subsequent treatment. Consistent use of existing resources (diagnostics and documentation) can help to avoid hypersensitivity reactions or to rapidly recognize and treat them, respectively.
Authors: Carolien M J van der Linden; Marieke C H Kerskes; Annemarie M H Bijl; Huub A A M Maas; Antoine C G Egberts; Paul A F Jansen Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: M Isabel Lucena; Mariam Molokhia; Yufeng Shen; Thomas J Urban; Guruprasad P Aithal; Raúl J Andrade; Christopher P Day; Francisco Ruiz-Cabello; Peter T Donaldson; Camilla Stephens; Munir Pirmohamed; Manuel Romero-Gomez; Jose Maria Navarro; Robert J Fontana; Michael Miller; Max Groome; Emmanuelle Bondon-Guitton; Anita Conforti; Bruno H C Stricker; Alfonso Carvajal; Luisa Ibanez; Qun-Ying Yue; Michel Eichelbaum; Aris Floratos; Itsik Pe'er; Mark J Daly; David B Goldstein; John F Dillon; Matthew R Nelson; Paul B Watkins; Ann K Daly Journal: Gastroenterology Date: 2011-04-12 Impact factor: 22.682
Authors: Amy L Cilia La Corte; Angela M Carter; Gillian I Rice; Qing Ling Duan; Guy A Rouleau; Albert Adam; Peter J Grant; Nigel M Hooper Journal: Hum Mutat Date: 2011-09-12 Impact factor: 4.878
Authors: Julie I Papay; Dawn Clines; Rezvan Rafi; Nancy Yuen; Susan D Britt; John S Walsh; Christine M Hunt Journal: Regul Toxicol Pharmacol Date: 2009-03-18 Impact factor: 3.271
Authors: Paola Nicoletti; Guruprasad P Aithal; Einar S Bjornsson; Raul J Andrade; Ashley Sawle; Marco Arrese; Huiman X Barnhart; Emmanuelle Bondon-Guitton; Paul H Hayashi; Fernando Bessone; Alfonso Carvajal; Ingolf Cascorbi; Elizabeth T Cirulli; Naga Chalasani; Anita Conforti; Sally A Coulthard; Mark J Daly; Christopher P Day; John F Dillon; Robert J Fontana; Jane I Grove; Pär Hallberg; Nelia Hernández; Luisa Ibáñez; Gerd A Kullak-Ublick; Tarja Laitinen; Dominique Larrey; M Isabel Lucena; Anke H Maitland-van der Zee; Jennifer H Martin; Mariam Molokhia; Munir Pirmohamed; Elizabeth E Powell; Shengying Qin; Jose Serrano; Camilla Stephens; Andrew Stolz; Mia Wadelius; Paul B Watkins; Aris Floratos; Yufeng Shen; Matthew R Nelson; Thomas J Urban; Ann K Daly Journal: Gastroenterology Date: 2016-12-30 Impact factor: 22.682
Authors: Ruwen Böhm; Leocadie von Hehn; Thomas Herdegen; Hans-Joachim Klein; Oliver Bruhn; Holger Petri; Jan Höcker Journal: PLoS One Date: 2016-06-21 Impact factor: 3.240
Authors: José Diogo S Souza; Maíra Fassoni-Ribeiro; Rayssa Miranda Batista; Juliana Mayumi Ushirohira; Antonio W Zuardi; Francisco S Guimarães; Alline C Campos; Flávia de Lima Osório; Daniel Elias; Cacilda S Souza; AndRea A Fassoni; Jaime E C Hallak; José Alexandre S Crippa Journal: Front Pharmacol Date: 2022-05-19 Impact factor: 5.988
Authors: Kazeem Adeola Oshikoya; Ibrahim Abayomi Ogunyinka; Comfort Kunak Ogar; Abiodun Abiola; Ali Ibrahim; Ibrahim Adekunle Oreagba Journal: Ther Adv Drug Saf Date: 2020-02-12